Primecap Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Primecap Management’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,000	Closed	-$5.22K	–	340
2022 Q4	$5.22K	Sell	12,000 -3,600	-23%	-$1.17K	﹤0.01%	334
2022 Q3	$4K	Sell	15,600 -1,100	-7%	-$377	﹤0.01%	335
2022 Q2	$6K	Sell	16,700 -1,600	-9%	-$662	﹤0.01%	341
2022 Q1	$12K	Sell	18,300 -1,800	-9%	-$1.53K	﹤0.01%	339
2021 Q4	$26K	Sell	20,100 -31,700	-61%	-$56.3K	﹤0.01%	342
2021 Q3	$112K	Sell	51,800 -525	-1%	-$1.14K	﹤0.01%	337
2021 Q2	$143K	Hold	52,325	–	–	﹤0.01%	333
2021 Q1	$137K	Sell	52,325 -300	-0.6%	-$849	﹤0.01%	327
2020 Q4	$146K	Sell	52,625 -600	-1%	-$1.75K	﹤0.01%	319
2020 Q3	$246K	Sell	53,225 -1,900	-3%	-$6.27K	﹤0.01%	309
2020 Q2	$155K	Sell	55,125 -18,700	-25%	-$60K	﹤0.01%	306
2020 Q1	$180K	Sell	73,825 -46,600	-39%	-$168K	﹤0.01%	290
2019 Q4	$617K	Sell	120,425 -2,862	-2%	-$15.9K	﹤0.01%	288
2019 Q3	$796K	Sell	123,287 -1,000	-0.8%	-$6.89K	﹤0.01%	286
2019 Q2	$774K	Sell	124,287 -7,251	-6%	-$55.2K	﹤0.01%	291
2019 Q1	$1.4M	Sell	131,538 -662	-0.5%	-$6.59K	﹤0.01%	277
2018 Q4	$1.05M	Sell	132,200 -3,163	-2%	-$45.6K	﹤0.01%	281
2018 Q3	$2.62M	Hold	135,363	–	–	﹤0.01%	279
2018 Q2	$2.45M	Sell	135,363 -12,675	-9%	-$187K	﹤0.01%	269
2018 Q1	$1.57M	Sell	148,038 -172,875	-54%	-$2.78M	﹤0.01%	273
2017 Q4	$13.5M	Sell	320,913 -105,437	-25%	-$4.73M	0.01%	225
2017 Q3	$23.5M	Buy	426,350 +9,200	+2%	+$1.55M	0.02%	200
2017 Q2	$77.4M	Buy	417,150 +57,284	+16%	+$10M	0.07%	153
2017 Q1	$43M	Buy	359,866 +269,928	+300%	+$28.3M	0.04%	176
2016 Q4	$8.94M	Sell	89,938 -2,662	-3%	-$280K	0.01%	229
2016 Q3	$10.4M	Hold	92,600	–	–	0.01%	223
2016 Q2	$9.51M	Sell	92,600 -2,525	-3%	-$252K	0.01%	224
2016 Q1	$8.74M	Sell	95,125 -963	-1%	-$103K	0.01%	225
2015 Q4	$13.9M	Sell	96,088 -662	-0.7%	-$86.2K	0.01%	209
2015 Q3	$10M	Buy	96,750 +34,250	+55%	+$4.02M	0.01%	219
2015 Q2	$10.2M	Buy	+62,500	New	+$10.6M	0.01%	220

Other funds holding SIOX

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

Primecap Management's SIOX Position: Q1 2023 in Review

Primecap Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2023, closing a stake of 12,000 shares — an estimated $5.22K sold.

Primecap Management first reported a position in SIOX in Q2 2015 and held it in 31 quarters. The position peaked at $77.4M in Q2 2017. 4 funds tracked by Wall St. Rank hold SIOX as of Q1 2023.

Primecap Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Primecap Management sold 12,000 Sio Gene Therapies Inc. Common Stock shares in Q1 2023, an estimated $5.22K.
Primecap Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 31 quarters.
Primecap Management's Sio Gene Therapies Inc. Common Stock position peaked at $77.4M in Q2 2017.
4 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2023.

Based on Primecap Management's 13F filing for Q1 2023, filed 15 May 2023.